Repligen Corporation announced that Karen A. Dawes will retire from its Board of Directors effective September 30, 2026, following over twenty years of service. The filing states her departure is not due to any disagreement with the company regarding operations or policies. Repligen operates in the biotechnology industry, providing equipment and services for the development and manufacturing of biological drugs.

Repligen Corporation announced that the Hart-Scott-Rodino antitrust waiting period for its proposed acquisition of BioLife Solutions expired on September 3, 2026. The transaction involves Repligen acquiring all outstanding shares of BioLife common stock for $11.25 cash and 0.1442 shares of Repligen common stock per share. Completion remains subject to customary closing conditions, including adoption by BioLife's stockholders at a special meeting scheduled for October 5, 2026. Repligen Corporation operates in the biotechnology industry, providing equipment, consumables, and services for the development and manufacture of biological drugs.

Repligen Corporation reported second quarter 2026 financial results and updated its full-year guidance. Q2 revenue reached $204 million, a 12% year-over-year increase, while GAAP operating income remained flat at $14 million. Adjusted operating income rose 55% to $34 million, and adjusted diluted EPS was $0.54. The company raised its full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09. Repligen also announced a definitive agreement to acquire BioLife Solutions to strengthen its cell therapy capabilities. The company operates in the life sciences industry, developing and commercializing bioprocessing technologies and systems for biological drug manufacturing.

On July 21, 2026, Repligen Corporation entered into a definitive merger agreement to acquire BioLife Solutions, Inc. for a total enterprise value of approximately $1.5 billion. BioLife stockholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock per share, totaling a value of $31.00 per share. The transaction is expected to close in the fourth quarter of 2026, subject to BioLife stockholder and regulatory approvals. Repligen expects the acquisition to be accretive to adjusted EPS by at least 5 cents in year one and 25 cents in year two, with anticipated synergies of $20 million in year one and $30 million in year two. Additionally, Repligen reported preliminary Q2 2026 revenue growth of approximately 12% reported and 13% organic. Repligen is a life sciences company that develops bioprocessing technologies for biological drug manufacturing.